NCT06161545View on ClinicalTrials.gov

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 24, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions
Stage II Squamous Cell Carcinoma of the Head and NeckStage III Squamous Cell Carcinoma of the Head and NeckStage IV Squamous Cell Carcinoma of the Head and Neck
Interventions
BIOLOGICAL

PD-L1 t-haNK cells

Irradiated PD-L1 t-haNK cells at a dose of 2 x 10\^9 administered via IV infusion over 30 minutes on Days 1, 5, 8, 12, and 15

DRUG

pembrolizumab

400 mg administered as a 30 minute IV infusion on Day 1

DRUG

N-803

15 ug/kg via subcutaneous injection on Day 1

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT06161545 - Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter